Theravance Biopharma, Inc. - Ordinary Share $0.00001 par value (TBPH)

Historical Holders from Q1 2014 to Q1 2025

Symbol
TBPH on Nasdaq
CUSIP
G8807B106
Type / Class
Equity / Ordinary Share $0.00001 par value
Shares outstanding
49M
All holders as of December 31, 2024
Q4 2024
Shares, excl. options
44.9M
Holdings value
$422M
% of all portfolios
0.001%
Grand Portfolio weight change
0%
Number of holders
127
Number of buys
61
Number of sells
-48
Average Value change %
+0%
Average buys %
+0%
Average sells %
0%
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Significant Owners of Theravance Biopharma, Inc. - Ordinary Share $0.00001 par value (TBPH)

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
Newtyn Management, LLC 9.7% $44.9M 4.76M Newtyn Management, LLC Dec 31, 2024

Institutional Holders of Theravance Biopharma, Inc. - Ordinary Share $0.00001 par value (TBPH)

Period Reported Shares, Excl. Options Value, Excl. Options Change Price Investors
2025 Q1 85.4K $763K +$50.2K $8.93 7
2024 Q4 44.9M $422M -$6.9M $9.41 127
2024 Q3 45.8M $369M -$13.8M $8.06 118
2024 Q2 47.1M $400M -$8.04M $8.48 129
2024 Q1 48M $430M -$11.5M $8.97 119
2023 Q4 48.8M $549M -$40.4M $11.24 116
2023 Q3 50.8M $439M -$16.2M $8.63 113
2023 Q2 52.3M $542M -$81.3M $10.35 116
2023 Q1 60.2M $653M -$19.3M $10.85 112
2022 Q4 62.1M $696M -$39.7M $11.22 117
2022 Q3 58.1M $589M -$970K $10.14 108
2022 Q2 59.2M $536M +$8.9M $9.06 104
2022 Q1 58M $554M +$32.3M $9.56 111
2021 Q4 52.8M $583M -$17.1M $11.05 105
2021 Q3 60.1M $445M -$37.8M $7.40 108
2021 Q2 60.7M $882M +$106M $14.52 101
2021 Q1 53.5M $1.09B +$7.58M $20.41 105
2020 Q4 53.2M $945M +$17.4M $17.77 101
2020 Q3 52.2M $772M -$4.43M $14.78 111
2020 Q2 52.2M $1.1B +$23.3M $20.99 117
2020 Q1 55.3M $1.28B +$249M $23.11 101
2019 Q4 44.8M $1.16B +$118M $25.89 101
2019 Q3 46.2M $900M -$26.3M $19.48 87
2019 Q2 36.3M $593M +$40M $16.33 91
2019 Q1 48.4M $1.1B +$14.6M $22.67 97
2018 Q4 47.7M $1.22B -$166K $25.59 92
2018 Q3 47.4M $1.55B +$9.88M $32.67 90
2018 Q2 47.8M $1.08B +$18.5M $22.68 82
2018 Q1 47.7M $1.16B +$19.3M $24.25 84
2017 Q4 46.9M $1.31B -$13.5M $27.89 79
2017 Q3 47.3M $1.62B +$33.5M $34.24 83
2017 Q2 46.2M $1.84B +$26.5M $39.84 90
2017 Q1 45.1M $1.66B +$168M $36.82 93
2016 Q4 43.8M $1.4B +$264M $31.88 96
2016 Q3 35.3M $1.28B +$76.6M $36.24 99
2016 Q2 33.9M $770M +$132M $22.69 94
2016 Q1 28M $526M +$42.7M $18.80 75
2015 Q4 25.9M $425M +$86.2M $16.39 77
2015 Q3 20.5M $226M -$24.5M $10.99 77
2015 Q2 22.2M $288M +$16.3M $13.02 83
2015 Q1 20.9M $362M +$7.47M $17.35 82
2014 Q4 20.3M $303M -$33.6M $14.92 85
2014 Q3 21.1M $486M +$14.3M $23.05 83
2014 Q2 20.2M $644M +$644M $31.88 87
2014 Q1 842 $14.6K $0 $17.35 1